Consolidated balance sheet
(in CHF 1 000)
|
|
|
Notes |
|
31.03.2021 |
|
31.12.2020 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
3 914 |
|
6 816 |
|
Receivables from brokers |
|
|
|
– |
|
1 521 |
|
Securities |
|
4 |
|
4 278 768 |
|
3 954 659 |
|
Other assets |
|
|
|
235 |
|
139 |
|
|
|
|
|
4 282 917 |
|
3 963 135 |
|
Total assets |
|
|
|
4 282 917 |
|
3 963 135 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
350 000 |
|
63 000 |
|
Payables to brokers |
|
|
|
8 455 |
|
6 576 |
|
Other short-term liabilities |
|
|
|
5 683 |
|
5 709 |
|
Tax liabilities |
|
|
|
326 |
|
303 |
|
|
|
|
|
364 464 |
|
75 588 |
|
Total liabilities |
|
|
|
364 464 |
|
75 588 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
6 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
6 |
|
– |
|
(8 241) |
|
Retained earnings |
|
|
|
3 907 373 |
|
3 884 708 |
|
|
|
|
|
3 918 453 |
|
3 887 547 |
|
Total liabilities and shareholders' equity |
|
|
|
4 282 917 |
|
3 963 135 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
70.75 |
|
70.30 |
The notes are an integral part of the condensed consolidated interim financial statements.
The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on April 20, 2021.